Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Hydroa Vacciniforme Patient Information Questions & Answers Department of Dermatology The aim of this leaflet is to give you information and answer some commonly asked questions about Hydroa Vacciniforme. What is Hydroa Vacciniforme? Hydroa Vacciniforme is a rare skin condition of unknown cause, in which there is abnormal sensitivity of the skin to sunlight. Although patients can be affected throughout the year, the condition is usually worse in the spring and summer months. After exposure to sunlight a tingling discomfort develops, followed by blisters of varying size on a red and swollen background. The blisters are filled with clear fluid which may become crusted and may eventually leave scars. This normally affects sun-exposed sites, usually the face, ears and backs of hands. Covered sites can rarely be affected. Who suffers from Hydroa Vaccinforme? Hydroa Vacciniforme normally starts in the first decade of life. Males and females are equally affected. Is Hydroa Vacciniforme serious? No, but it can restrict your lifestyle, particularly during the summer months and on holidays. Once it occurs, patients need to cover up, stay out of the sun, and wait for it to settle. Through time, most patients can judge how long they can stay out in the sun. It is important to try and prevent acute flare ups because of the risk of scarring. How would I know I have Hydroa Vacciniforme? We are normally able to diagnose Hydroa Vacciniforme from the patient’s history and examination findings. Investigations/tests Investigations are performed to rule out other conditions. These include blood tests and phototesting. Phototesting is conducted with light test equipment. Different doses of ultraviolet and visible light are shone on your back to measure your sensitivity to light. Page 1 of 3 Can the rash be prevented? Many people find that by adopting sun protective measures such as the avoidance of sunlight between 11am and 3pm and using broad spectrum high protection factor helps to prevent recurrence. What treatments are there? Sun avoidance, hats, clothing and high factor sun screens can help. Some patients may find a desensitisation course of UVB light therapy helpful. Patients are treated three times a week for five weeks, and this allows them to stay out longer in sunlight. A desensitisation course toughens up your skin with the use of artificial sunlight. The effect is lost over the winter months, so desensitisation has to be repeated yearly. Be sure to eat a diet rich in Vitamin D, for example oily fish or take a vitamin D or cod liver oil supplement if you are avoiding sunlight exposure. How can I treat the eruption if it occurs? With the use of steroid ointments or creams to reduce redness and discomfort. Also the use of moisturiser to soothe the skin. Can I get rid of Hydroa Vacciniforme? Some people report a progr essive improvement in late adolescence and it can resolve by early adulthood. Is Hydroa Vacciniforme infectious? No. There is no risk of other people developing the condition after coming into contact with you. Can I go abroad? Yes, but this depends on the severity of your skin state. Many sufferers can manage with precautions, such as, seeking out the shade, suitable clothing, using a hat and high factor sunscreens. Which sunscreen should I use? We suggest the use of a broad spectrum, high factor (at least SPF30) sun screen, applied regularly during sunlight exposure. Your doctor will advise you on these. Page 2 of 3 Contact Numbers: Ninewells Hospital Phototherapy Department Telephone: 01382 632264 Ward 24 Telephone: 01382 633824 Perth Royal Infirmary Dermatology Treatment Centre Telephone: 01738 473516 Stracathro Hospital Dermatology Treatment Centre Telephone: 01356 665208 Developed by Dermatology Department and reviewed by patients and staff. Reviewed: 09/2014 Review: 09/2016 LN0744 Page 3 of 3